Clinical trials: in China
Relapsed/Refractory AL Amyloidosis
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.
- Trial name
- NCT07250269
- Testing
- GC012F Injection
- Where
- 9 sites in China
- Volunteers
- 12 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 6 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Psoriasis, Ankylosing Spondylitis
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
The goal of this clinical trial is to (PART 1) to evaluate the safety and tolerability of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics…
- Trial name
- NCT07920861
- Testing
- HB0017 Injection
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Huabo Biopharm Co., Ltd.
Palmoplantar Pustulosis of Adults
A Trial Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulosis
The study is being conducted to evaluate the efficacy and safety of SHR-1139 injection.
- Trial name
- NCT07923851
- Testing
- SHR-1139 Injection
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Epithelial Ovarian Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with…
- Trial name
- TREVI-OC-02 (NCT07851025)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 220 sites in United States, Argentina and 27 more
- Volunteers
- 950 people
- Sponsor
- AstraZeneca
Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
To Evaluate the Safety, Tolerability, and Preliminary Antitumor Efficacy of RC148 in Combination with Telisotuzumab adizutecan as First-line Treatment for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
- Trial name
- NCT07874282
- Testing
- Telisotuzumab adizutecan plus RC148(ABBV-1480)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RemeGen Co., Ltd.
Bradycardia Sinus, AV Block
The CT-verified Data Collection Study to Investigate the Correlation Between the Leadless Pacemaker Tip Location and Echo, ECG
The goal of this observational study is to assess inter-/intra- ventricular synchrony and ECG characteristics in relation to Micra tip location.
- Conditions
- Bradycardia Sinus, AV Block, Atrial Fibrillation (AF)
- Trial name
- NCT06910059
- Testing
- Observational
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
This study is a multicenter, randomized, double-blind (with open-lable semaglutide 1.0 mg, active comparator), placebo-and active-controlled, parallel-group Phase 2 clinical trial aimed at evaluating the efficacy, safety and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM
- Trial name
- NCT07923357
- Testing
- SAL0150 dose 1, SAL0150 dose 2, SAL0150 dose 3
- Where
- China
- Volunteers
- 364 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Overweight, Obesity
A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity
The purpose of this study is to learn about: How PF-08653944 is changed and removed from the body after taken Safety of PF-08653944 The extent to which side effects can be tolerated after taking PF- 08653944 for the possible…
- Conditions
- Overweight, Obesity, Healthy Adults
- Trial name
- NCT07845513
- Testing
- PF-08653944
- Where
- China
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)
This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy…
- Trial name
- NCT07888569
- Testing
- DZD8586, Rabeprazole
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT07235202
- Testing
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel
- Where
- 18 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Triple-Negative Breast Cancer (TNBC)
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
- Trial name
- NCT07208149
- Testing
- MR001 Bispecific Antibody for Injection
- Where
- 3 sites in China
- Volunteers
- 42 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
This study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- ACCESS-1 (NCT05133531)
- Testing
- Ravulizumab, Pozelimab, Cemdisiran
- Where
- 68 sites in United States, Brazil and 22 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumors, Breast Cancer
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant in subjects with…
- Conditions
- Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT07923214
- Testing
- CG-7321
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma.
- Trial name
- NCT06977581
- Testing
- PF-07275315
- Where
- 137 sites in United States, Argentina and 13 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Soft Tissue Sarcoma, Non-small Cell Lung Cancer
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
This study is a single-center, open-label, phase I dose-escalation clinical trial, aiming to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, as well as the preliminary efficacy of…
- Trial name
- NCT07920822
- Testing
- 177Lu-HX02 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in…
- Trial name
- NCT04736706
- Testing
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab
- Where
- 262 sites in United States, Australia and 33 more
- Volunteers
- 1,688 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Participants, Ulinastatin
Pharmacokinetics, Safety and Tolerability of Single Sequential and Multiple Intravenous Infusions of Ulinastatin for Injection in Healthy Chinese Participants
This is a Phase 1 clinical study. The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of ulinastatin for injection after single sequential and multiple continuous intravenous infusions in…
- Trial name
- NCT07923578
- Testing
- Ulinastatin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Ocular Myasthenia Gravis
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.
- Trial name
- MyVisionXT (NCT07465289)
- Testing
- Rozanolixizumab
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 100 people
- Sponsor
- UCB Biopharma SRL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.